cancer risk with semaglutide Popular obesity medications significantly lower overall risk, study finds. The breakthrough class of obesity medications, including GLP-1 receptor agonists like and dual GLP-1/GIP receptor agonists like tirzepatide, continue to make glp 1 pancreatic cancer risk

We reviewed Sikiric 1993-2026 (Zagreb, over 150 BPC-157 papers), the AJSM 2026 systematic review (35 preclinical studies), the 2026 pilot PK study in two healthy subjects, and the February 2026 STAT review

It may be appropriate for adults with type 2 diabetes who need improved blood-sugar control and, in certain cases, cardiovascular or kidney-risk reduction

Different doors to the same room

10.1093/nar/gku077 33 HuangJ.RauscherS.NawrockiG.RanT.FeigM.de GrootB

Lipid metabolism and liver inflammation II Fatty liver disease and fatty acid oxidation

Protection from toxic proteins: These drugs may reduce accumulation of beta-amyloid and tau proteins in the brain